C&L: Lichter tapped to run Akesis

Akesis Pharmaceuticals has appointed Jay Lichter, Ph.D., a veteran biotechnology and pharmaceutical business executive, as its new president and CEO. Dr. Lichter replaces Edward B. Wilson, who has resigned from the company to pursue other opportunities.

Todd Pope has left his post as CEO of Liquidia Technologies to take the worldwide president's post at Cordis Cardiovascular, a J&J company. Board member Steve Nelson will take the interim position until a permanent replacement is found. Liquidia also named Robert "Bob" L. Henn as chief technology officer and Christopher "Chris" H. Price, Ph.D. as head of life sciences.

William "Obi" Greenman has been named to the newly-created position of president, Cerus Europe.

Cubist Pharmaceuticals announced the death Sunday of Francis P. "Frank" Tally, the company's chief scientific officer.

John Ratliff has been appointed as Quintiles Transnational's new COO.

Norway's DiaGenic ASA has appointed Erik Christensen, MD PhD, as its new managing director.

James E. Dentzer has been appointed CFO of Amicus Therapeutics.

ORIDIS Biomed has appointed Wolfgang Senne as CFO.

Innovive Pharmaceuticals has named J. Gregory Jester vice president and CFO.

Plexxikon has named Fletcher Payne to the position of vice president and CFO.

Penny Heaton, M.D., has been appointed to the newly-created position of chief medical officer at Novavax.

Archemix has named James Gilbert, M.D., chief medical officer and senior vice president of clinical and regulatory affairs.

Cerimon Pharmaceuticals has named Timothy J. McBride senior vice president of business development.

InforSense announced that David Hadfield has joined the company as COO.

Helix BioMedix announced that Lori H. Bush has been named COO.

China's Renhuang Pharmaceuticals has appointed Edith Kong as CFO.

Peter Powchik, M.D., has been chosen as senior vice president of clinical development at Regeneron Pharmaceuticals.

Amylin Pharmaceuticals announced that Joe A. Young has been appointed senior vice president, marketing.

Transport Pharmaceuticals has named Navneet "Tony" Sharma vice president of quality systems and operational excellence.

Chiltern International has named Paul Westnedge to head up Chiltern Integrated Resourcing Solutions UK.

Aptuit has named Dr. Marcello DiMare to the new position of senior director, chemistry development within the company's active pharmaceutical ingredient business line.

Frank Xu has been chosen as national sales manager for China at Beijing Med-Pharm.

Calvert Research Institute announced that it has hired Sara Shen as a business analyst.

Lorus Therapeutics has named Georg Ludwig and Dr. Michael Moore as directors of the company.

Ligand Pharmaceuticals has elected Jason M. Aryeh, founder and general partner of JALAA Equities, LP, to its board of directors.

CardioVascular BioTherapeutics has named Grant Gordon vice chairman of its board of directors.

PharmaNet Development Group announced that Peter Tombros and Rolf Classon have been appointed to its board of directors.

NanoBio has named Robert C. Moellering, Jr., M.D., to its board.

Dorothy H. Bray, Ph.D., will chair the Scientific Advisory Board at CytoDyn.

Viral Genetics has added two Harvard Medical School immunology and virology specialists to its Scientific Advisory Board: Drs. Marcus Altfeld and Todd M. Allen.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.